PCM
TXMD icon

Piermont Capital Management’s TherapeuticsMD TXMD Stock Holding History

Piermont Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,567
Closed -$1.09M – 281
2016
Q2 		$1.09M Buy
2,567
+1,242
+94% +$512K 0.28% 134
2016
Q1 		$424K Buy
+1,325
New +$452K 0.14% 176

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Piermont Capital Management's TXMD Position: Q3 2016 in Review

Piermont Capital Management sold out of TherapeuticsMD (TXMD) in Q3 2016, closing a stake of 2,567 shares — an estimated $1.09M sold.

Piermont Capital Management first reported a position in TXMD in Q1 2016 and held it in 2 quarters. The position peaked at $1.09M in Q2 2016. 137 funds tracked by Wall St. Rank hold TXMD as of Q3 2016.

  • Piermont Capital Management reported no remaining TherapeuticsMD position as of Q3 2016 after selling out during the quarter.
  • Piermont Capital Management sold 2,567 TherapeuticsMD shares in Q3 2016, an estimated $1.09M.
  • Piermont Capital Management first reported a position in TherapeuticsMD in Q1 2016 and held it in 2 quarters.
  • Piermont Capital Management's TherapeuticsMD position peaked at $1.09M in Q2 2016.
  • 137 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2016.

Based on Piermont Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.